U.S. markets open in 6 hours 52 minutes
  • S&P Futures

    4,245.50
    +9.25 (+0.22%)
     
  • Dow Futures

    33,936.00
    +101.00 (+0.30%)
     
  • Nasdaq Futures

    14,298.75
    +40.50 (+0.28%)
     
  • Russell 2000 Futures

    2,298.00
    +5.50 (+0.24%)
     
  • Crude Oil

    73.08
    +0.02 (+0.03%)
     
  • Gold

    1,779.70
    +2.30 (+0.13%)
     
  • Silver

    25.91
    +0.05 (+0.20%)
     
  • EUR/USD

    1.1936
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.4720
    0.0000 (0.00%)
     
  • Vix

    16.66
    -1.23 (-6.88%)
     
  • GBP/USD

    1.3955
    +0.0008 (+0.06%)
     
  • USD/JPY

    110.8590
    +0.2240 (+0.20%)
     
  • BTC-USD

    34,133.13
    +1,420.60 (+4.34%)
     
  • CMC Crypto 200

    819.72
    +25.39 (+3.20%)
     
  • FTSE 100

    7,090.01
    +27.72 (+0.39%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

How Much Are Oragenics, Inc. (NYSEMKT:OGEN) Insiders Spending On Buying Shares?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize!

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So we’ll take a look at whether insiders have been buying or selling shares in Oragenics, Inc. (NYSEMKT:OGEN).

What Is Insider Selling?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market. However, rules govern insider transactions, and certain disclosures are required.

We don’t think shareholders should simply follow insider transactions. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, ‘insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.’

Check out our latest analysis for Oragenics

Oragenics Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Robert Koski bought US$71k worth of shares at a price of US$0.42 per share. Although we like to see insider buying, we note that this large purchase was at significantly lower prices. It may not shed much light on insider confidence at the current share price.

You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

AMEX:OGEN Recent Insider Trading, February 22nd 2019
AMEX:OGEN Recent Insider Trading, February 22nd 2019

I will like Oragenics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Based on our data, Oragenics insiders have about 3.1% of the stock, worth approximately US$816k. But they may have an indirect interest through a corporate structure that we haven’t picked up on. We consider this fairly low insider ownership.

What Might The Insider Transactions At Oragenics Tell Us?

It doesn’t really mean much that no insider has traded Oragenics shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. While we have no worries about the insider transactions, we’d be more comfortable if they owned more Oragenics stock. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.